Proteostasis Therapeutics, Inc. (NASDAQ: PTI) was founded in 2006, formerly known as Proteoguard, Inc., changed to its current name in September 2007, headquartered in Cambridge, Massachusetts, USA, with 42 full-time employees, is a biopharmaceutical company The company develops new therapies for the treatment of protein conformation diseases.
Proteostasis Therapeutics (PTI):
Proteostasis Therapeutics, Inc. is a biopharmaceutical company that focuses on the development of treatments for protein configuration diseases. PTI provides improved treatments for cyst fibrosis; it also develops treatments for disease defects such as protein folding, transportation and clearance caused by the imbalance of the proteostasis system. Including genetic, neurodegenerative and retinal degenerative diseases.
Proteostasis Therapeutics products include:
1. Proteostasis Therapeutics’ leading product candidate- PTI-428 , an oral, bioavailable, cystic fibrosis transmembrane conductance regulator modulator, currently in phase II research.
2. The company also developed- PTI-801 , a correction molecule.
3. The company has also developed PTI-808 , a synergist molecule that has completed Phase I research.
Proteostasis Therapeutics, Inc. and Astellas Pharma Inc. have signed a cooperation agreement to research and screen the treatment of UPR pathway.
Proteostasis Therapeutics (PTI) investment:
Proteostasis Therapeutics landed on Nasdaq on February 11, 2016, with an issue price of US$8, issuing 6,250,000 shares, raising US$50,000,000, and stock code: PTI.